Research programme: chemokine antagonists - Evolutec
Latest Information Update: 19 Mar 2008
At a glance
- Originator Evolutec
- Mechanism of Action Chemokine receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Autoimmune disorders
Most Recent Events
- 11 Jan 2002 Preclinical development for Autoimmune disorders in United Kingdom (Unknown route)